Wednesday, February 12, 2025
spot_img

ARMOUR Residential REIT, Inc. Fourth Quarter 2024 Webcast Scheduled for February 13, 2025

VERO BEACH, Florida, Feb. 11, 2025 (GLOBE NEWSWIRE) — ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) (“ARMOUR” or the “Company”) announced today that it will provide an online, real‑time webcast of its conference call with equity analysts covering fourth quarter 2024 operating results on Thursday, February 13, 2025. The Company will issue its fourth quarter 2024 earnings release after the close of trading on Wednesday, February 12, 2025.

The live broadcast will be available on February 13, 2025, beginning at 9:00 a.m. (Eastern Time) at https://event.choruscall.com/mediaframe/webcast.html?webcastid=JUgGiqtR.

The online replay will be available on the Company’s website www.armourreit.com and continue for one year.

About ARMOUR Residential REIT, Inc.
ARMOUR invests primarily in fixed rate residential, adjustable rate and hybrid adjustable rate residential mortgage-backed securities issued or guaranteed by U.S. Government-sponsored enterprises or guaranteed by the Government National Mortgage Association. ARMOUR is externally managed and advised by ARMOUR Capital Management LP, an investment advisor registered with the Securities and Exchange Commission (“SEC”).

Additional Information and Where to Find It
Investors, security holders and other interested persons may find additional information regarding the Company at the SEC’s internet site at www.sec.gov, or the Company website at www.armourreit.com, or by directing requests to: ARMOUR Residential REIT, Inc., 3001 Ocean Drive, Suite 201, Vero Beach, Florida 32963, Attention: Investor Relations.

Investor Contact:
Gordon M. Harper
Chief Financial Officer
ARMOUR Residential REIT, Inc.
(772) 617-4340

Powered by SlickText.com

Hot this week

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

Also entered into collaboration and option agreement with AbbVie...

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary...

P10 Reports Fourth Quarter and Full Year 2024 Earnings Results

Generated Record Quarterly Revenue of $85 Million, a 35%...

Bitdeer Announces January 2025 Production and Operations Update

- First trial batch of SEALMINER A2 air cooled...

Topics

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

Also entered into collaboration and option agreement with AbbVie...

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary...

P10 Reports Fourth Quarter and Full Year 2024 Earnings Results

Generated Record Quarterly Revenue of $85 Million, a 35%...

Bitdeer Announces January 2025 Production and Operations Update

- First trial batch of SEALMINER A2 air cooled...

Eminent Closes Acquisition of Celts Project in Nevada

VANCOUVER, British Columbia, Feb. 12, 2025 (GLOBE...

Optiva Launches Agentic AI for Telecom BSS, Powered by Google’s Gemini Models

Award-winning BSS platform now seamlessly incorporates virtual generative AI...
spot_img

Related Articles

Popular Categories

spot_img